SINO BIOPHARM: LM-350 "CDH17 ADC" completes the enrollment of the first patient in Phase I clinical trial in Australia
I'm PortAI, I can summarize articles.
SINO BIOPHARM announced that its wholly-owned subsidiary, Lixin Pharmaceutical Technology, has completed the enrollment of the first patient in the Phase I clinical trial of the innovative drug LM-350 "CDH17 ADC" in Australia, marking the entry of this drug into the clinical development stage. LM-350 is an antibody-drug conjugate targeting CDH17, demonstrating significant anti-tumor activity, particularly in certain drug-resistant colorectal cancer cells. The study will evaluate the safety and preliminary efficacy of LM-350 in patients with advanced solid tumors
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments